J&J drug unit to leverage Singapore's biotech hub
'Very lively biotech hub' spurs pharmaceutical arm's external collaborations
Add BT as a preferred source
Annabeth Leow
Singapore
JOHNSON & Johnson's (J&J) regional pharmaceutical head believes that Singapore offers innovation, research and development tie-up opportunities, even as wider insurance coverage in the Asia-Pacific is expected to fuel growth for drugmakers.
Ong Ai Hua, the group chairman for Janssen Asia Pacific, the pharmaceutical arm of J&J, told The Business Times that "our focus in Singapore is on innovation - not so much on manufacturing".
TRENDING NOW
Why China is tightening controls on overseas stock trading
Xi Jinping has just rewritten the rules of US-China rivalry
‘Even a CEO’s job can be replaced by AI’: DBS CEO Tan Su Shan bets big on agentic AI
‘Whole deck of cards just toppled’: FoodXervices’ Nichol Ng on how a 92-year-old family business unravelled – and what’s next
